Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors

New approaches for the management of glioblastoma (GBM) are an urgent and unmet clinical need. Here, we illustrate that the efficacy of radiotherapy for GBM is strikingly potentiated by concomitant therapy with the arginine-depleting agent ADI-PEG20 in a non-arginine-auxotrophic cellular background (argininosuccinate synthetase 1 positive). Moreover, this combination led to durable and complete radiological and pathological response, with extended disease-free survival in an orthotopic immune-competent model of GBM, with no significant toxicity. ADI-PEG20 not only enhanced the cellular sensitivity of argininosuccinate synthetase 1–positive GBM to ionizing radiation by elevated production of nitric oxide (˙NO) and hence generation of cytotoxic peroxynitrites, but also promoted glioma-associated macrophage/microglial infiltration into tumors and turned their classical antiinflammatory (protumor) phenotype into a proinflammatory (antitumor) phenotype. Our results provide an effective, well-tolerated, and simple strategy to improve GBM treatment that merits consideration for early evaluation in clinical trials.

Fondo de Desarrollo Regional (FEDER). Programa Operativo Epiro 2014-2020

National Strategic Reference Frameworks de la Unión Europea. NSRF 2014-2020-5033092

Ministerio de Ciencia, Innovación y Universidades de España y fondos FEDER. RTI2018-098645-B-100

Consejería de Economía y Conocimiento de la Junta de Andalucía y fondos FEDER. P18- RT-1372

Universidad de Sevilla. US-1264806

Premio Trimestral Publicación Científica Destacada de la US. Facultad de Farmacia